Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
109.39
+4.16 (3.95%)
At close: Aug 13, 2025, 4:00 PM
106.89
-2.50 (-2.29%)
After-hours: Aug 13, 2025, 7:53 PM EDT
Axsome Therapeutics Stock Forecast
Stock Price Forecast
According to 16 professional analysts, the 12-month price target for Axsome Therapeutics stock ranges from a low of $143 to a high of $216. The average analyst price target of $176.56 forecasts a 61.40% increase in the stock price over the next year.
Price Target: $176.56 (+61.40%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 7 | 6 |
| Buy | 8 | 8 | 8 | 9 | 10 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 15 | 16 | 17 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $173 → $176 | Strong Buy | Maintains | $173 → $176 | +60.89% | Aug 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $184 → $189 | Buy | Maintains | $184 → $189 | +72.78% | Aug 5, 2025 |
| Needham | Needham | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +37.12% | Aug 4, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $190 | Buy | Initiates | $190 | +73.69% | Jul 3, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $193 → $186 | Buy | Maintains | $193 → $186 | +70.03% | Jun 12, 2025 |
Financial Forecast
Revenue This Year
623.36M
from 385.69M
Increased by 61.62%
Revenue Next Year
991.24M
from 623.36M
Increased by 59.02%
EPS This Year
-3.64
from -5.99
EPS Next Year
1.52
from -3.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 701.0M | 1.2B | 1.9B | ||
| Avg | 623.4M | 991.2M | 1.5B | ||
| Low | 569.6M | 797.7M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 81.8% | 86.9% | 95.4% | ||
| Avg | 61.6% | 59.0% | 54.2% | ||
| Low | 47.7% | 28.0% | 7.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.94 | 5.26 | 16.09 | ||
| Avg | -3.64 | 1.52 | 9.21 | ||
| Low | -4.36 | -2.49 | 2.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 959.5% | ||
| Avg | - | - | 506.6% | ||
| Low | - | - | 48.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.